The bacterial ecosystem residing in our gut, known as the gut microbiota, has a profound influence on our health. Bacterial colonisation of the infant gut begins at birth and the ecosystem continues to develop until three years of age. Early life bacterial colonisation represents a crucial period of gastrointestinal, immune, and brain development that has important lifelong health impacts.
Bifidobacteria are the first microbial infant gut colonisers and typically predominate in the intestines of healthy breastfed infants. Their predominance in the stools of healthy infants was described more than 100 years ago, suggesting the human milk contained “bifidogenic factors” that stimulated the growth of these keystone beneficial bacteria.
Human milk is considered as the gold standard of infant nutrition. It is rich in unique, complex sugars called human milk oligosaccharides (HMOs), which contains between 12-14 g/L (in mature milk) of over 200 structurally different HMOs. These sugars comprise the third largest component of milk, after lactose and fat, yet offer no direct nutritive value for infants since their structural complexity renders them non-digestible. As it turns out, HMOs are not food for the infants, but food for beneficial gut bacteria which function in shaping a healthy infant gut microbiota. However, HMO utilisation is not equally observed across all bifidobacteria as many strains are not able to grow well on HMOs.
A leading dairy company from Japan has developed a proprietary probiotics strain of Bifidobacterium longum subsp. infantis that possesses immense capacity to utilise HMOs and good potential for human health.
The proprietary probiotics strain of Bifidobacterium infantis is a clinically effective, unique probiotic strain that possesses superior colonisation potential. With its immense capacity to utilise HMOs, the proprietary strain of Bifidobacterium infantis gains a competitive growth advantage in infant gut. It is a probiotics strain that well-adapted to the intestinal environment of humans, especially infants. Ingestion of this probiotics strain is specifically effective at improving the colonisation of bifidobacteria in infant gut and potentially beneficial at improving gut well-being and mental state.
The proprietary probiotics strain of Bifidobacterium infantis is available as a functional probiotics ingredient for application and development in various finished products. It can be incorporated in nutritional supplements, infant formula, and oil drop products for promoting infant health. It possesses good potentials for human health and thus can be used to develop a wide range of nutritive finished products.
The proprietary probiotics strain of Bifidobacterium infantis is a unique probiotics strain that possesses the highest capability to utilise HMOs and great potential to colonise the human gut. It exploits the full benefits of human milk for developing infants, which selectively reinforces the beneficial commensal bifidobacteria during infancy. Backed with scientific evidence, this strain is a worthy human-residential bifidobacteria (HRB) that can provide feasible solutions that work, last and extraordinary to B2B manufacturers in the probiotics industry for product development.